


**IN THE CLAIMS**

Claims 1-23 (cancelled).

Claim 24 (currently amended) A method of treatment of the human or non-human body to combat an inflammatory disease, autoimmune disease or tissue rejection, wherein said method comprises administering to said body a compound of formula I.



wherein Ar<sub>1</sub> and Ar<sub>2</sub> are phenyl optionally substituted with hydroxy, thiol, C<sub>1</sub>-C<sub>6</sub> alkoxy, cyano or halo and R<sub>2</sub> is H or C<sub>1</sub>-C<sub>10</sub> alkyl, provided that the relative weight ratio of any 3, 5-pyrazoladine dione not having a 4-hydroxy group (impurity) to said compound of formula I is not more than 50 parts impurity to 50 parts formula I.

Claim 25 (currently amended) A method as claimed in claim [[1]] 24 wherein said disease is selected from Addison's disease, Beçhet's syndrome, diabetes mellitus, haemolytic anaemia, lupus erythematosus, multiple sclerosis, myasthenia gravis, pernicious anaemia, polyglandular deficiency, polymyositis, dermatomyositis, testicular failure, thrombocytopenic purpura, Crohns disease, ulcerative colitis and rheumatoid arthritis.

Claim 26 (currently amended) A method as claimed in claim [[2]] 25 wherein said disease is diabetes mellitus or rheumatoid arthritis.

Claim 27 (currently amended) A method as claimed in claim [[1]] 24 wherein Ar<sub>1</sub> is phenyl, Ar<sub>2</sub> is p-hydroxy phenyl, and R<sub>2</sub> is [[C<sub>1</sub>H<sub>9</sub> ]] C<sub>4</sub>H<sub>9</sub>.

Claim 28 (new) A method as claimed in claim 24 wherein said relative weight ratio of any 3,5-pyrazoladine dione not having a 4-hydroxy group to said compound of formula I is not more than 10 parts impurity to 90 parts formula I.